Skip to main content

06-27-2021 | ADA 2021 | Conference coverage | Video

SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes

Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes (6:00).

Read transcript

Related content

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

EASD Annual Meeting 2021 coverage

Access all of our ongoing coverage including the latest news and expert video interviews.

Image Credits